Biotech RadarJobs updated

COMPANY

Seres Therapeutics

HQ: Cambridge, MA source · serestherapeutics.com ↗

Clinical Phase 3

Keywords: microbiome gastroenterology Clostridioides Difficile Infection Clostridium Difficile Infection Ulcerative Colitis Allogeneic Hematopoietic Stem Cell Transplantation Clostridium Difficile SER-109 SER-287 SER-155 SER-262

Location: Cambridge, MA · source · Oct 15, 2026

Profile checked Oct 10, 2026

8Trials (company is sponsor)

Timeline

  1. Trial start Phase 1: A Multiple Dose Study to Evaluate Safety, Tolerability, PK, and Efficacy of SER-155 in Adults Undergoing HSCT source ↗
  2. Trial start Phase 2: A Study to Assess Efficacy and Safety of SER-287 in Adults With Active Mild-to-Moderate Ulcerative Colitis source ↗
  3. Trial start Phase 3: ECOSPOR IV: An Open-Label Study Evaluating SER-109 in Recurrent Clostridioides Difficile Infection source ↗
  4. Trial start Phase 3: ECOSPOR III - SER-109 Versus Placebo in the Treatment of Adults With Recurrent Clostridium Difficile Infection source ↗
  5. Trial start Phase 1: SER-262 Versus Placebo in Adults With Primary Clostridium Difficile Infection to Prevent Recurrence source ↗
  6. Trial start Phase 1: A Study to Evaluate the Safety, Tolerability and Microbiome Dynamics of SER-287 in Subjects With Mild-to-Moderate Ulcerative Colitis source ↗
  7. Trial start Phase 2: SER-109 Versus Placebo to Prevent Recurrent Clostridium Difficile Infection (RCDI) source ↗

Clinical trials (lead sponsor) 8

RecordTitlePhaseStatusStartPrimary completion
NCT04995653A Multiple Dose Study to Evaluate Safety, Tolerability, PK, and Efficacy of SER-155 in Adults Undergoing HSCTPhase 1CompletedNov 24, 2021Jul 23, 2024 (actual)
NCT02437500Expanded Access Program of SER-109 in the Treatment of Adults With Recurrent Clostridioides Difficile Infection (RCDI)Not listedApproved for marketingNot listedNot listed
NCT03183128ECOSPOR III - SER-109 Versus Placebo in the Treatment of Adults With Recurrent Clostridium Difficile InfectionPhase 3CompletedJul 10, 2017Jul 3, 2020 (actual)
NCT03183141ECOSPOR IV: An Open-Label Study Evaluating SER-109 in Recurrent Clostridioides Difficile InfectionPhase 3CompletedOct 23, 2017Apr 29, 2022 (actual)
NCT02830542SER-262 Versus Placebo in Adults With Primary Clostridium Difficile Infection to Prevent RecurrencePhase 1Completed2016-082018-05 (actual)
NCT03759041A Study to Assess Efficacy and Safety of SER-287 in Adults With Active Mild-to-Moderate Ulcerative ColitisPhase 2TerminatedDec 19, 2018May 28, 2021 (actual)
NCT02618187A Study to Evaluate the Safety, Tolerability and Microbiome Dynamics of SER-287 in Subjects With Mild-to-Moderate Ulcerative ColitisPhase 1CompletedJan 13, 2016Dec 6, 2017 (actual)
NCT02437487SER-109 Versus Placebo to Prevent Recurrent Clostridium Difficile Infection (RCDI)Phase 2Completed2015-052016-07 (actual)

Raises and investors new

Form D raises come from the company’s own SEC filing (last 2 years).

Feedback